---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-24-000029"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:22:46.025662+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lisata Q1 net loss $5.4M; ASCEND Phase 2b data on track for Q4 2024

## Summary
- Cash, equivalents and marketable securities $43.3M as of Mar 31, 2024; funding operations into early 2026.
- Net loss $5.4M vs $6.2M in Q1 2023; operating expenses $6.6M, down 3.6% YoY.
- Top-line data from pivotal Phase 2b ASCEND trial (mPDAC) expected Q4 2024; full data set mid-2025.
- Received FDA Orphan Drug and Rare Pediatric Disease designations for certepetide in osteosarcoma.
- BOLSTER (cholangiocarcinoma) enrollment completion expected Q3 2024; CENDIFOX on track for year-end 2024.

## SEC filing metadata
- accession: 0000320017-24-000029
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001724000029/0000320017-24-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001724000029/clbs-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-24-000029
- JSON: https://secwatch.observer/filing/0000320017-24-000029.json
- Plain text: https://secwatch.observer/filing/0000320017-24-000029.txt

## Key facts
- Earnings Releases
  LISATA THERAPEUTICS, INC. updated its the three months ended March 31, 2024 guidance (reaffirmed).
  - Period: the three months ended March 31, 2024
  - Guidance: reaffirmed
  - Result: reported results
  source text: Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000032001724000029/0000320017-24-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.